Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform

Rhea-AI Summary

Fifty 1 Labs (OTC: FITY) outlined plans for a U.S.-focused telehealth peptide services platform designed as a patient-facing complement to its peptide science and commercialization activities, while remaining separate from investigational clinical-development programs.

The planned model is expected to support digital intake, scheduling of virtual or in‑person consultations, and evaluation by appropriately licensed healthcare professionals, including physicians, nurse practitioners, naturopathic doctors where permitted, and other qualified clinicians. When a peptide therapy is deemed medically appropriate and legally available, prescriptions may be routed to qualified compounding pharmacies for dispensing.

According to the company, potential revenue streams may include monthly memberships, virtual visit fees, care-management services, lab and monitoring coordination, patient-support services, and pharmacy-related service arrangements where allowed. Fifty 1 Labs plans to structure the platform in compliance with federal and state healthcare, telemedicine, pharmacy, privacy, advertising, and professional-practice rules. Launch timing remains dependent on regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support

VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.

The planned platform is expected to allow patients to complete digital intake, schedule virtual or in-person consultations, and receive evaluation by appropriately licensed healthcare professionals. Where a clinician determines that a peptide therapy is medically appropriate and legally available, prescriptions may be transmitted to qualified compounding pharmacies for dispensing. The Company expects that clinical services may be supported by licensed physicians, nurse practitioners, naturopathic doctors where authorized by state law, and other qualified clinicians acting within the scope of their licensure.

Fifty 1 Labs anticipates that the telehealth service line may generate revenue through monthly membership fees, virtual visit fees, care-management services, laboratory and monitoring coordination, patient-support services, and pharmacy-related service arrangements where legally permissible. The Company intends to structure such arrangements in compliance with federal and state healthcare laws, telemedicine rules, pharmacy and compounding requirements, fee-splitting limitations, referral rules, advertising restrictions, privacy laws, and professional-practice requirements.

"Telehealth can improve access, but it must be built with the right guardrails," said Joel J. Gagnier, Ph.D., MSc, N.D., Chief Executive Officer of Fifty 1 Labs. "Our priority is to create a clinically responsible model with appropriate intake, documentation, medical oversight, monitoring, patient education, adverse-event processes, and compliance review."

The Company does not intend to represent that any peptide is approved for a use for which it is not approved. The timing and launch of the telehealth service line remain subject to regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing.

About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services. The Company's strategy includes R&D, partnerships, potential acquisitions, clinical-development planning, and commercialization pathways where legally permissible.

Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1labs.com

Forward-Looking Statements

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, identified by words such as "may," "will," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, involve risks and uncertainties that could cause actual results to differ materially from those projected. Such risks include, but are not limited to, general economic conditions, competition, technological changes, and other factors detailed in the company's Disclosure Statements. The company undertakes no obligation to update these statements.

SOURCE: Fifty 1 Labs, Inc.

View the original press release on ACCESS Newswire

FAQ

What telehealth peptide platform did Fifty 1 Labs (FITY) announce on August 7, 2026?

Fifty 1 Labs announced plans for a U.S.-focused telehealth peptide services platform offering digital intake, virtual or in-person consultations, and clinician evaluation for peptide therapies. According to the company, the platform is intended to complement its peptide science and commercialization strategy while remaining separate from investigational clinical programs.

How will the planned Fifty 1 Labs (FITY) telehealth peptide service generate revenue?

The company expects the telehealth service may generate revenue from monthly membership fees, virtual visit fees, care-management services, lab and monitoring coordination, and patient-support services. According to Fifty 1 Labs, pharmacy-related service arrangements may also contribute where such structures are legally permissible under applicable federal and state regulations.

Which clinicians will provide care in Fifty 1 Labs (FITY) planned telehealth peptide platform?

According to Fifty 1 Labs, clinical services may be provided by licensed physicians, nurse practitioners, naturopathic doctors where authorized by state law, and other qualified clinicians. These professionals are expected to act within the scope of their licensure when evaluating patients and determining whether peptide therapies are medically appropriate.

What compliance measures will Fifty 1 Labs (FITY) apply to its telehealth peptide service?

Fifty 1 Labs intends to structure the platform to comply with federal and state healthcare laws, telemedicine rules, pharmacy and compounding requirements, fee-splitting and referral rules, advertising restrictions, privacy laws, and professional-practice standards. The company also highlights processes for documentation, medical oversight, monitoring, and adverse-event handling.

When will Fifty 1 Labs (FITY) launch its U.S. telehealth peptide services platform?

The company has not provided a specific launch date for the telehealth platform. According to Fifty 1 Labs, timing depends on regulatory review, clinician contracting, pharmacy integration, technology development, insurance arrangements, state-by-state legal analysis, and securing sufficient financing to support the service line.

Will Fifty 1 Labs (FITY) promote unapproved uses of peptide therapies in its telehealth service?

According to Fifty 1 Labs, it does not intend to represent that any peptide is approved for a use for which it is not approved. The company emphasizes that prescriptions will be considered only when therapies are medically appropriate and legally available in the relevant jurisdiction.